PROFESSIONAL EDITION

The largest community of pharma leaders

Uncategorized

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer

MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the first patient was dosed in DESTINY-CRC02,...

Embracing Digital Marketing in Times of Pandemic: Six Questions with Lucy Fisher

Lucy Fisher analyses the importance of embracing digital marketing and facing the challenge of the pandemic, especially for small organisations and charities. Lucy Fisher is...

Dicerna Announces Roche’s Initiation of GalXC™ RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that...

Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of...

Recent Articles